stockrowBeam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −16.7%
- Free cash flow
- −29.5%
Quarter to September 2026, against a year earlier
Follow BEAM
Alert me
Beam Therapeutics Inc. (BEAM) Total debt
Beam Therapeutics Inc.'s total debt at the end of fiscal 2022 was $182.0M, up 23.0% from $148.0M in fiscal 2021. At the end of the quarter to 30 September 2026 it was $100.4M. Over the past ten years it has ranged from $1.0M (fiscal 2017) to $182.0M (fiscal 2022) — the current reading is the highest in ten years. Beam Therapeutics Inc. ranks 87th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $182.0M | 22.97% |
| FY2021 | $148.0M | 38.32% |
| FY2020 | $107.0M | 234.38% |
| FY2019 | $32.0M | 3,100.00% |
| FY2017 | $1.0M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $100.4M | 0.11% |
| Jun 2026 | $100.3M | 0.06% |
| Mar 2026 | $100.2M | (37.77%) |
| Sep 2023 | $161.0M | (2.42%) |
| 15 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | $575.9M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | $252.4M |
| VRDN Viridian Therapeutics, Inc. compare | $242.2M |
| XNCR Xencor, Inc. compare | $119.7M |
| RCUS Arcus Biosciences, Inc. compare | $102.0M |
| BEAM Beam Therapeutics Inc. | $100.4M |
| IDYA IDEAYA Biosciences, Inc. compare | $2.1M |
| NAMS NewAmsterdam Pharma Company N.V. compare | $94.9K |
| MBX MBX Biosciences, Inc. compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on BEAM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement